Ocular Manifestations in Rheumatoid Arthritis
DOI:
https://doi.org/10.33192/Smj.2022.41Keywords:
Rheumatoid arthritis, connective tissue disease, autoimmune disease, ocular manifestations, eye involvementAbstract
Rheumatoid arthritis (RA) is an inflammatory rheumatic disease that generally damages synovial-line joints. Extra-articular manifestations of RA have been reported in cases of multiorgan involvement. These manifestations can occur in the hematologic and cardiovascular system, lungs, kidneys, and eyes. Various ocular manifestations of RA have been previously reported including keratoconjunctivitis sicca, conjunctivitis, uveitis, scleritis, retinal vascular occlusion, optic neuritis, and amaurosis fugax. It is important to recognize these ocular issues as manifestations of RA since they can sometimes be a response marker for the onset of an immune reactivation. Urgent management of ocular complications is essential to manage sight-threatening complications and prevent further damage to the eyes.
References
Harper SL, Foster CS. The ocular manifestations of rheumatoid disease. Int Ophthalmol Clin. 1998;38(1):1-19.
Thomas DC, Kohli D, Chen N, Peleg H, Almoznino G. Orofacial manifestations of rheumatoid arthritis and systemic lupus erythematosus: a narrative review. Quintessence Int. 2021;52(5):454-66.
Moreland LW, Curtis JR. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Semin Arthritis Rheum. 2009;39(2):132-43.
Widdifield J, Paterson JM, Bernatsky S, Tu K, Tomlinson G, Kuriya B, et al. The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis Rheumatol. 2014;66(4):786-93.
Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85(3):307-10.
Prada J, Noelle B, Baatz H, Hartmann C, Pleyer U. Tumour necrosis factor alpha and interleukin 6 gene expression in keratocytes from patients with rheumatoid corneal ulcerations. Br J Ophthalmol. 2003;87(5):548-50.
Messmer EM, Foster CS. Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea. 1995;14(4):408-17.
Kang MH, Kim MK, Lee HJ, Lee HI, Wee WR, Lee JH. Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Sci. 2011;26(7):938-44.
Fujita M, Igarashi T, Kurai T, Sakane M, Yoshino S, Takahashi H. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol. 2005;140(5):808-13.
Tong L, Thumboo J, Tan YK, Wong TY, Albani S. The eye: a window of opportunity in rheumatoid arthritis? Nat Rev Rheumatol. 2014;10(9):552-60.
Pepose JS, Akata RF, Pflugfelder SC, Voigt W. Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjogren's syndrome. Ophthalmology. 1990;97(12):1599-605.
Fox RI. Sjogren's syndrome: evolving therapies. Expert Opin Investig Drugs. 2003;12(2):247-54.
Usuba FS, de Medeiros-Ribeiro AC, Novaes P, Aikawa NE, Bonfiglioli K, Santo RM, et al. Dry eye in rheumatoid arthritis patients under TNF-inhibitors: conjunctival goblet cell as an early ocular biomarker. Sci Rep. 2020;10(1):14054.
Bhamra MS, Gondal I, Amarnani A, Betesh S, Zhyvotovska A, Scott W, et al. Ocular Manifestations of Rheumatoid Arthritis: Implications of Recent Clinical Trials. Int J Clin Res Trials. 2019;4(2).
Murray PI, Rauz S. The eye and inflammatory rheumatic diseases: The eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Pract Res Clin Rheumatol. 2016;30(5):802-25.
Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012;119(1):43-50.
Young S. Ocular involvement in connective tissue disorders. Curr Allergy Asthma Rep. 2005;5(4):323-6.
Boonsopon S, Choopong P, Wongwijitsook W, Sopitviriyaporn W, Tesavibul N. Non-Infectious Scleritis and Systemic Collagen Vascular Disease Association. Siriraj Med J. 2020;72(4):352-60.
Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol. 2007;3(4):219-26.
Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995;102(4):687-92.
Fong LP, Sainz de la Maza M, Rice BA, Kupferman AE, Foster CS. Immunopathology of scleritis. Ophthalmology. 1991;98(4):472-9.
Bernauer W, Watson PG, Daicker B, Lightman S. Cells perpetuating the inflammatory response in scleritis. Br J Ophthalmol. 1994;78(5):381-5.
Di Girolamo N, Lloyd A, McCluskey P, Filipic M, Wakefield D. Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol. 1997;150(2):653-66.
Artifoni M, Rothschild PR, Brezin A, Guillevin L, Puechal X. Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(2):108-16.
Sims J. Scleritis: presentations, disease associations and management. Postgrad Med J . 2012;88(1046):713-8.
McCluskey PJ, Watson PG, Lightman S, Haybittle J, Restori M, Branley M. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology. 1999;106(12):2380-6.
Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130(4):469-76.
Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Scleritis therapy. Ophthalmology. 2012;119(1):51-8.
Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984;91(10):1253-63.
Murray PI, Rahi AH. Pathogenesis of Mooren's ulcer: some new concepts. Br J Ophthalmol. 1984;68(3):182-7.
Messmer EM, Foster CS. Vasculitic peripheral ulcerative keratitis. Surv Ophthalmol. 1999;43(5):379-96.
Riley GP, Harrall RL, Watson PG, Cawston TE, Hazleman BL. Collagenase (MMP-1) and TIMP-1 in destructive corneal disease associated with rheumatoid arthritis. Eye. 1995;9 ( Pt 6):703-18.
Smith VA, Rishmawi H, Hussein H, Easty DL. Tear film MMP accumulation and corneal disease. Br J Ophthalmol. 2001;85(2):147-53.
Smith VA, Hoh HB, Easty DL. Role of ocular matrix metalloproteinases in peripheral ulcerative keratitis. Br J Ophthalmol. 1999;83(12):1376-83.
Boonsopon S, Anesi S. Retinal Vasculitis: Fundamentals, Diagnostics, and Management. Siriraj Med J. 2021;73:493-500.
Androudi S, Dastiridou A, Symeonidis C, Kump L, Praidou A, Brazitikos P, et al. Retinal vasculitis in rheumatic diseases: an unseen burden. Clin Rheumatol. 2013;32(1):7-13.
Wilkinson M, Torrance WN. Clinical background of rheumatoid vascular disease. Ann Rheum Dis. 1967;26(6):475-80.
Turesson C, Matteson EL. Vasculitis in rheumatoid arthritis. Curr Opin Rheumatol. 2009;21(1):35-40.
Matsuo T, Masuda I, Matsuo N. Geographic choroiditis and retinal vasculitis in rheumatoid arthritis. Jpn J Ophthalmol. 1998;42(1):51-5.
Giordano N, D'Ettorre M, Biasi G, Fioravanti A, Moretti L, Marcolongo R. Retinal vasculitis in rheumatoid arthritis: an angiographic study. Clin Exp Rheumatol. 1990;8(2):121-5.
Vollertsen RS, Conn DL, Ballard DJ, Ilstrup DM, Kazmar RE, Silverfield JC. Rheumatoid vasculitis: survival and associated risk factors. Medicine. 1986;65(6):365-75.
Itty S, Pulido JS, Bakri SJ, Baratz KH, Matteson EL, Hodge DO. Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis. Trans Am Ophthalmol Soc. 2008;106:75-81; discussion 81-3.
Vignesh AP, Srinivasan R. Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies. Clin Ophthalmol. 2015;9:393-7.
Promelle V, Goeb V, Gueudry J. Rheumatoid Arthritis Associated Episcleritis and Scleritis: An Update on Treatment Perspectives. J Clin Med. 2021;10(10).
Petznick A, Tong L, Chung R, Wang JC, Koh M, Salleh R, et al. Autologous plasma eyedrops prepared in a closed system: a treatment for dry eye. Eye. 2013;27(9):1102.
Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opin Oharmacother. 2011;12(3):325-34.
Liu J, Kuszynski CA, Baxter BT. Doxycycline induces Fas/Fas ligand-mediated apoptosis in Jurkat T lymphocytes. Biochem Biophys Res Commun. 1999;260(2):562-7.
Watson PG. The diagnosis and management of scleritis. Ophthalmology. 1980;87(7):716-20.
Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol. 2005;50(4):351-63.
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Group B. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122-7.
Jinesh S. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology. 2015;23(2-3):71-7.
St Clair EW. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis. 2002;61(Suppl 2):ii67-9.
Li DQ, Lokeshwar BL, Solomon A, Monroy D, Ji Z, Pflugfelder SC. Regulation of MMP-9 production by human corneal epithelial cells. Exp Eye Res. 2001;73(4):449-59.
Fox DA. Cytokine blockade as a new strategy to treat rheumatoid arthritis: inhibition of tumor necrosis factor. Arch Intern Med. 2000;160(4):437-44.
Ashok D, Ayliffe WH, Kiely PD. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. Rheumatology. 2005;44(7):950-1.
Hernandez-Illas M, Tozman E, Fulcher SF, Jundt JW, Davis J, Pflugfelder SC. Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens. 2004;30(1):2-5.
Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 2007;27(4):399-413.
Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113(12):2317-23.
Sassa Y, Kawano Y, Yamana T, Mashima T, Ishibashi T. A change in treatment from etanercept to infliximab was effective to control scleritis in a patient with rheumatoid arthritis. Acta Ophthalmol. 2012;90(2):e161-2.
Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45(3):252-7.
Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea. 2012;31(1):90-1.
Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323-32.
Cordero-Coma M, Salom D, Diaz-Llopis M, Lopez-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. 2011;118(9):1892 e3-4.
William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):231-3.
Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013;31(2):320-1.
Mesquida M, Victoria Hernandez M, Llorenc V, Pelegrin L, Espinosa G, Dick AD, et al. Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21(2):160-2.
Faez S, Lobo AM, Sobrin L, Papaliodis GN. Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Exp Ophthalmol. 2014;42(4):392-5.
Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine. 1992;4(1):1-5.
Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxford). 2007;46(6):1042-3.
Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67-81.
Wendling D, Dernis E, Prati C, Frisch E, Delbosc B. Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J Rheumatol. 2011;38(10):2284.
Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18(3):223-5.
Bonnet I, Rousseau A, Duraffour P, Pouchot J, Nguyen CD, Gabison E, et al. Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis. RMD Open. 2021;7(1):e001472.
Selmi C, Generali E, Massarotti M, Bianchi G, Scire CA. New treatments for inflammatory rheumatic disease. Immunol Res. 2014;60(2-3):277-88.
Meadow PB, Nguyen J, Kesavarapu K. Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis. Case reports in rheumatology. 2014;2014:403452.
Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol. 2008;35(9):1897-8.
Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res. 2010;62(6):821-5.
Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res. 2011;63(2):307-8; author reply 308.
Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(2):297-300.
Acharya M, Dave A. Commentary: Corneal involvement in rheumatoid arthritis. Indian J Ophthalmol. 2021;69(1):73-4.
Ho LJ, Lai JH. Small-molecule inhibitors for autoimmune arthritis: Success, failure and the future. Eur J Pharmacol. 2015;747:200-5.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:
- Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
